And in yet another clinical trial in which bladder cancer patients were treated with ipilimumab, it was found that treatment-induced no consistent changes in Treg frequencies (CD4+Foxp3+, CD4+Foxp3+ICOShi, or CD4+Foxp3+ICOSlo T cells) (Liakou et al., 2008). Here, FOXP3 is linked to urinary bladder carcinoma.